ArticleCancer research2013
MyoD is a tumor suppressor gene in medulloblastoma.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Active repression of muscle fate preserves neural lineage identity during cerebellum development.bioRxiv : the preprint server for biology · 2026Article
- Mediator complex subunit 8 promotes bladder cancer progression via Stearoyl-CoA desaturase.Cellular and molecular life sciences : CMLS · 2026Article
- CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD.Journal of translational medicine · 2025Article
- MyoD1 promotes the transcription of BIK and plays an apoptosis-promoting role in the development of gastric cancer.Cell cycle (Georgetown, Tex.) · 2024Article
- PRC2 disruption in cerebellar progenitors produces cerebellar hypoplasia and aberrant myoid differentiation without blocking medulloblastoma growth.Acta neuropathologica communications · 2023Article
- Development of Nystagmus With the Absence of MYOD Expression in the Extraocular Muscles.Investigative ophthalmology & visual science · 2021Article
- scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.Nature communications · 2019Article
- Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.Annals of clinical and translational neurology · 2019Review
- A Genome-Wide Analysis of the Penumbral Volume in Inbred Mice following Middle Cerebral Artery Occlusion.Scientific reports · 2019Article
- The untold stories of the speech gene, theGenes & cancer · 2018Review
- Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma.Cell reports · 2017Article
- Identification of MyoD-Responsive Transcripts Reveals a Novel Long Non-coding RNA (lncRNA-AK143003) that Negatively Regulates Myoblast Differentiation.Scientific reports · 2017Article
- Inhibitory effect of MyoD on the proliferation of breast cancer cells.Oncology letters · 2016Article
- Genetic and molecular alterations across medulloblastoma subgroups.Journal of molecular medicine (Berlin, Germany) · 2015Review
- MiR-206, a Cerebellum Enriched miRNA Is Downregulated in All Medulloblastoma Subgroups and Its Overexpression Is Necessary for Growth Inhibition of Medulloblastoma Cells.Journal of molecular neuroscience : MN · 2015Article
- Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells.Nature protocols · 2015Article
- Insights into the Transcriptional Architecture of Behavioral Plasticity in the Honey Bee Apis mellifera.Scientific reports · 2015Article
- Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers.Cancer biology & therapy · 2015Review
- Generation of skeletal muscle cells from pluripotent stem cells: advances and challenges.Frontiers in cell and developmental biology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 3 countries.
Funding
Abstract
While medulloblastoma, a pediatric tumor of the cerebellum, is characterized by aberrations in developmental pathways, the majority of genetic determinants remain unknown. An unbiased Sleeping Beauty transposon screen revealed MyoD as a putative medulloblastoma tumor suppressor. This was unexpected, as MyoD is a muscle differentiation factor and not previously known to be expressed in cerebellum or medulloblastoma. In response to deletion of one allele of MyoD, two other Sonic hedgehog-driven mouse medulloblastoma models showed accelerated tumor formation and death, confirming MyoD as a tumor suppressor in these models. In normal cerebellum, MyoD was expressed in the proliferating granule neuron progenitors that are thought to be precursors to medulloblastoma. Similar to some other tumor suppressors that are induced in cancer, MyoD was expressed in proliferating medulloblastoma cells in three mouse models and in human medulloblastoma cases. This suggests that although expression of MyoD in a proliferating tumor is insufficient to prevent tumor progression, its expression in the cerebellum hinders medulloblastoma genesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.